Article info
Uterine Cancer
Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer
- Address correspondence and reprint requests Maysa M. Abu-Khalaf, MBBS, Section of Medical Oncology, Yale University School of Medicine, Yale Comprehensive Cancer Center, 300 George Street, Suite 120, New Haven, CT 06511. E-mail: maysa.abu-khalaf{at}yale.edu.
Citation
Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer
Publication history
- Received September 13, 2013
- Accepted December 8, 2013
- First published March 1, 2014.
Online issue publication
March 01, 2014
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright © 2014 by IGCS and ESGO